Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its...

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable...

Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company’s recent announcement that it will provide its new gene therapy...

Odyssey Therapeutics, Inc. announces pricing of its upsized IPO of 15,500,000 shares of its common stock at an IPO price of $18 per share.

ICP-488 is expected to provide a novel therapeutic option for patients. There are no approved targeted therapies for Sjögren's syndrome globally.

Kraig Labs (OTCQB: KBLB) is the leader in the global race to commercialize spider silk, validated science and advancing production capability.

Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the...

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Mabylon AG leveraged Asimov's lead optimization offering, Rapid Pools, to de-risk candidate selection before advancing into cell line development.